Literature DB >> 24178189

Development of universal influenza vaccines based on influenza virus M and NP genes.

M Zheng1, J Luo, Z Chen.   

Abstract

PURPOSE: Vaccination is the safest and most effective measure against influenza virus infections. However, traditional influenza vaccines cannot respond effectively to an unforeseen epidemic or pandemic caused by a virus with antigenic drifts or antigenic shifts. Therefore, developing a universal influenza vaccine (UIV) that induces broad-spectrum and long-term immunity has become a major trend in influenza vaccine research and development.
METHODS: This article reviews the development of UIVs based on these conserved influenza virus proteins. RESULTS AND
CONCLUSION: The matrix protein (M1, M2) and nucleoprotein (NP) of influenza viruses have highly conserved sequences, and they become the major target antigens of current UIV studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24178189     DOI: 10.1007/s15010-013-0546-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  69 in total

Review 1.  Novel generations of influenza vaccines.

Authors:  George Kemble; Harry Greenberg
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

2.  Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors:  M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

3.  Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine.

Authors:  Jacob Atsmon; Efrat Kate-Ilovitz; Dimitry Shaikevich; Yossi Singer; Inna Volokhov; Kirsten Y Haim; Tamar Ben-Yedidia
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

4.  Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le.

Authors:  Tamar Ben-Yedidia
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.217

5.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

6.  Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier.

Authors:  Roxana M Ionescu; Craig T Przysiecki; Xiaoping Liang; Victor M Garsky; Jiang Fan; Bei Wang; Robert Troutman; Yvette Rippeon; Elizabeth Flanagan; John Shiver; Li Shi
Journal:  J Pharm Sci       Date:  2006-01       Impact factor: 3.534

7.  Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype.

Authors:  Keith Ameiss; Shamaila Ashraf; Wei Kong; Andrew Pekosz; Wai-Hong Wu; David Milich; Jean-Noel Billaud; Roy Curtiss
Journal:  Vaccine       Date:  2010-08-05       Impact factor: 3.641

8.  Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.

Authors:  V A Slepushkin; J M Katz; R A Black; W C Gamble; P A Rota; N J Cox
Journal:  Vaccine       Date:  1995       Impact factor: 3.641

9.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

10.  Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Authors:  Richard D Antrobus; Tamara K Berthoud; Caitlin E Mullarkey; Katja Hoschler; Lynda Coughlan; Maria Zambon; Adrian V S Hill; Sarah C Gilbert
Journal:  Mol Ther       Date:  2013-07-08       Impact factor: 11.454

View more
  27 in total

1.  Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

Authors:  Wenling Wang; Renqing Li; Yao Deng; Ning Lu; Hong Chen; Xin Meng; Wen Wang; Xiuping Wang; Kexia Yan; Xiangrong Qi; Xiangmin Zhang; Wei Xin; Zhenhua Lu; Xueren Li; Tao Bian; Yingying Gao; Wenjie Tan; Li Ruan
Journal:  Clin Vaccine Immunol       Date:  2015-04-01

2.  Chimeric hemagglutinin vaccine elicits broadly protective CD4 and CD8 T cell responses against multiple influenza strains and subtypes.

Authors:  Hsin-Yu Liao; Shih-Chi Wang; Yi-An Ko; Kuo-I Lin; Che Ma; Ting-Jen Rachel Cheng; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

3.  The surge of universal influenza vaccines.

Authors:  Antonio Cassone
Journal:  Pathog Glob Health       Date:  2017-02-20       Impact factor: 2.894

4.  M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection.

Authors:  D G Eliasson; A Omokanye; K Schön; U A Wenzel; V Bernasconi; M Bemark; A Kolpe; K El Bakkouri; T Ysenbaert; L Deng; W Fiers; X Saelens; N Lycke
Journal:  Mucosal Immunol       Date:  2017-03-01       Impact factor: 7.313

5.  Heterosubtypic influenza protection elicited by double-layered polypeptide nanoparticles in mice.

Authors:  Lei Deng; Timothy Z Chang; Ye Wang; Song Li; Shelly Wang; Shingo Matsuyama; Guoying Yu; Richard W Compans; Jian-Dong Li; Mark R Prausnitz; Julie A Champion; Bao-Zhong Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-31       Impact factor: 11.205

6.  Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice.

Authors:  Hartinio N Nahampun; Brad Bosworth; Joan Cunnick; Mark Mogler; Kan Wang
Journal:  Plant Cell Rep       Date:  2015-02-13       Impact factor: 4.570

7.  Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.

Authors:  Mei Zheng; Fen Liu; Yiqing Shen; Shilei Wang; Wenting Xu; Fang Fang; Bing Sun; Zhenyuan Xie; Ze Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza Virus.

Authors:  Xiaohui Li; Peter Pushko; Irina Tretyakova
Journal:  J Vaccines Vaccin       Date:  2015-06-30

Review 9.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

Review 10.  Universal influenza virus vaccines and therapeutic antibodies.

Authors:  R Nachbagauer; F Krammer
Journal:  Clin Microbiol Infect       Date:  2017-02-12       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.